Why Do We Not Assess Sympathetic Nervous System Activity in Heart Failure Management: Might GRK2 Serve as a New Biomarker?

Heart failure (HF) represents the end-stage condition of several structural and functional cardiovascular diseases, characterized by reduced myocardial pump function and increased pressure load. The dysregulation of neurohormonal systems, especially the hyperactivity of the cardiac adrenergic nervou...

Descripción completa

Detalles Bibliográficos
Autores principales: Bencivenga, Leonardo, Palaia, Maria Emiliana, Sepe, Immacolata, Gambino, Giuseppina, Komici, Klara, Cannavo, Alessandro, Femminella, Grazia Daniela, Rengo, Giuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7924864/
https://www.ncbi.nlm.nih.gov/pubmed/33669936
http://dx.doi.org/10.3390/cells10020457

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7924864/
https://www.ncbi.nlm.nih.gov/pubmed/33669936
http://dx.doi.org/10.3390/cells10020457

Ejemplares similares